Agendia Will Present AI Breast Cancer Test Analysis
Researchers plan to share findings on a digital pathology tool that could improve genomic testing access.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you trust artificial intelligence to provide accurate diagnostic information for serious medical conditions?
Agendia will present new research on an AI-driven digital pathology approach for breast cancer at the ESMO Congress 2026 in Madrid. The presentation is scheduled for October 24, 2026.
Why it matters
AI-driven digital pathology is being developed to potentially expand global access to genomic testing in breast cancer. This approach aims to streamline how molecular risk is assessed for patients.
The FLEX Study has compiled data from over 25,000 patients, including genomic profiles and clinical outcomes. Researchers are using this platform to evaluate an AI-driven analysis of whole slide images, though the comparative efficacy remains under investigation.
The players
Agendia
A precision oncology company based in Amsterdam and Irvine that develops genomic diagnostic tests like MammaPrint and BluePrint.
The details
The AI-driven method works by analyzing routine whole slide images of breast cancer tissue to provide molecular insights. It functions alongside established tools like MammaPrint, an FDA-cleared 70-gene test that assesses the risk of distant metastasis, and BluePrint, an 80-gene molecular subtyping assay. By integrating these genomic signatures with whole transcriptome profiling, the approach seeks to simplify the assessment process.
Timeline
The ESMO Congress 2026 takes place October 23 to 27, 2026.
The podium presentation regarding AI-driven digital pathology is set for October 24, 2026.
Health Landscape
This research builds upon the foundation of the FLEX Study to advance diagnostic accessibility. It represents a broader industry shift toward integrating AI with established molecular assays like MammaPrint to optimize cancer care.
This development in digital pathology may eventually lead to faster or more accessible diagnostic testing options for patients with early-stage breast cancer. Discuss whether genomic testing is appropriate for your specific cancer diagnosis with your oncologist.
The takeaway
AI tools in pathology are aimed at simplifying how breast cancer is subtyped and assessed for metastasis risk. Patients should remain informed about the genomic testing options their care team uses to guide treatment decisions.
Further reading
For more information on current diagnostic trends and developments, visit our Cancer section.
Source note: This article includes information reported by AFP.
Live Poll
Do you trust artificial intelligence to provide accurate diagnostic information for serious medical conditions?
